In its See Your Risks campaign, Bayer takes aim at denial among millennials and Gen Xers when it comes to heart disease. To younger generations, heart disease may seem like a far-away risk relegated ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...

Bayer plans to launch Acoramidis, a treatment for a rare heart disease called transthyretin amyloid cardiomyopathy, near the end of the first quarter, as well as elinzanetant, a non-hormonal ...

This collaboration supports the "Protect Your Heart" national awareness campaign, sponsored by Bayer and Al-Dawaa Medical ...

Regulatory filings underway for a third indication for darolutamide in prostate cancer and new indication for finerenone in patients with heart failure ... reinforcing Bayer’s leadership in ...

Bayer Leverkusen boss Xabi Alonso was delighted with the reaction his side showed after they won a dramatic DFB-Pokal quarter ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients ...